- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04694456
Pro-inflammatory Cytokines in Facioscapulohumeral Muscular Dystrophy (CYTOKINE-FSH) (CYTOKINE-FSH)
November 14, 2023 updated by: Centre Hospitalier Universitaire de Nice
Pro-inflammatory Cytokines as Potential Therapeutic Target in Type 1 Facioscapulohumeral Muscular Dystrophy: Pilot Study
The facial-glenohumeral muscular dystrophy type 1 (DMFSH1) is characterized by a selective and asymmetrical involvement of the facial muscles, the shoulder girdle and the anterolateral lodge legs.
Genetically, the disease is transmitted in an autosomal dominant manner and is caused by a pathogen contraction of repeat units (UR) say D4Z4 localized to the telomeric portion of chromosome 4qA.
The loss of UR causes hypomethylation of DNA and chromatin relaxation of the region that lead to inappropriate expression of DUX4 retrogene highly toxic.
The inappropriate expression induces a T cell reaction inflammatory response that participate and increase muscle damage.
In favor of this hypothesis, several muscle MRI studies have shown that atrophy and fibro-adipose degeneration (hyper signal in T1) were preceded by the appearance of muscle inflammation (hyper signal T2STIR) confirmed on histologically and dysregulation of genes involved in adaptive and innate immunity.
scientific hypothesis and potential benefits: the investigateur hypothesize that in patients of DMFSH1, the immune system cells may participate in the pathophysiology of the disease through changes in serum secretion of one or more cytokines and / or a modification of the response of inflammatory cells in some cell damage stimuli.
Design: this is a single-center pilot study, interventional.
In this study, the investigator will assay the serum cytokines and changes in peripheral blood cells of the expression of cytokines in response to some stimuli in 20 patients with Type 1 DMFSH genetically confirmed at an intermediate stage of clinical disease (kept walking, but at least one muscle of lower limbs reached) and compare with controls from the CYTOKINAGE study.
The investigator will also carry patients clinical testing (MMT sum score) and functional (6minute test march MFM) and a MRI not injected whole body (T1 sequences + and T2STIR) to study the relationship between these parameters and secretion cytokines or serum in response to certain stimuli Main objective: to compare serum levels of IL-6 in patients with DMFSH and controls.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Nice, France
- CHU de Nice
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- male or female age 18 to 75
- suffering from genetically confirmed FSHD1 (<11 D4Z4 repeat units on permissive chromosome 4 allele)
- ambulant or walking with assistance
- Manual Muscle Testing ≥4 for 1 of lower limb muscles
Exclusion Criteria:
- pregnancy or breast feeding
- stay in tropical/subtropical country within 3 months
- physical exercice within 10 hours
- specific diet (e.g. hypocaloric or cholesterol lowering diet)
- regular alcohol consumption; drug consumption within 3 months
- immunosuppressive or immonumodulating drug within 2 weeks or for more than 3 months withing last 6 months
- vaccination, blood transfusion of immunoglobulin treatment within 3 months
- infection within 3 weeks; HIV, HBV, HCV seropositivity
- chronic inflammatory and/or autoimmune or allergic disease from the gut (Crohn disease, ulcerative colitis), skin (psoriasis, atopic dermatitis), joints (rhumatoid arthritis), nervous system (multiple sclerosis), diabetes type I and II
- neurodegenerative disorders (Alzheimer's or Parkinson's diseases)
- diagnosed cancer not under remission for at least 5 years
- participation in the last 3 months in a research clinical trial with exposure to a pharmaceutical product or a medical device
- muscular MRI contraindication
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Facioscapulohumeral muscular dystrophy
Adult ambulant patients with facioscapulohumeral muscular dystrophy type 1 (FSHD1)
|
Mesure of cytokines concentration in serum
Other Names:
patient must walk during 6 minutes on a flat surface
test performed to evaluate the patient muscular weakness
scale allowing the evaluation of patient posture and upper body movements
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of serum IL-6 levels between FSHD1 patients and control subjects (from other previous studies) comparable in terms of age and sex
Time Frame: 21 months
|
Serum IL-6 levels will be measured using v-plex technology (MSD) in FSHD1 patients and compared with results obtained in paired control subjects from 2 cohorts (NCT00998231 and Cytokinage study NCT02660723)
|
21 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of serum levels of 28 oher pro-inflammatory cytokines between FSHD1 patients and control subjects
Time Frame: 21 months
|
Serum levels of 28 other cytokines will be measured using v-plex technology (MSD) in FSHD1 patients and compared with results obtained in paired control subjects
|
21 months
|
Comparison of cytokines produced upon in vitro stimulation of blood cells in FSHD1 patients and control subjects
Time Frame: 21 months
|
Cytokine production will be induced in blood cells by non-specific stimulation with LPS, ATP+LPS-EB or poly (I:C) in FSHD1 patients and compared with results obtained in control subjects
|
21 months
|
Evaluation of potential correlations between cytokines levels (either in the serum or produced upon in vitro stimulation) and clinical severity in FSHD1 patients
Time Frame: 21 months
|
Clinical severity and muscle impairment will be evaluated using standardized clinical scales (Manual Muscle Testing, Motor Function Measure-32, 6-minute walk test, age-corrected Clinical Severity Score)
|
21 months
|
Evaluation of potential correlations between cytokines levels (either in the serum or produced upon in vitro stimulation) and muscle MRI caracteristics in FSHD1 patients
Time Frame: 21 months
|
Whole body MRI will be recorded (T1 and T2STIR sequences) in order to evaluate muscle oedema, inflammation and degeneration
|
21 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 30, 2018
Primary Completion (Actual)
May 18, 2021
Study Completion (Actual)
May 18, 2021
Study Registration Dates
First Submitted
December 31, 2020
First Submitted That Met QC Criteria
December 31, 2020
First Posted (Actual)
January 5, 2021
Study Record Updates
Last Update Posted (Actual)
November 15, 2023
Last Update Submitted That Met QC Criteria
November 14, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16-AOI-13
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Muscular Dystrophies
-
Assistance Publique - Hôpitaux de ParisRecruitingLimb Girdle Muscular DystrophiesFrance
-
aTyr Pharma, Inc.CompletedLimb-Girdle Muscular Dystrophies | Facioscapulohumeral Muscular DystrophyUnited States, Denmark, France
-
Wake Forest University Health SciencesMuscular Dystrophy AssociationCompletedMuscular Dystrophies, Limb-Girdle (GENETICALLY CONFIRMED)United States
-
Virginia Commonwealth UniversityWashington University School of Medicine; University of Iowa; University of Minnesota and other collaboratorsRecruitingMuscular Dystrophies | Limb Girdle Muscular DystrophyUnited States, United Kingdom
-
Sarepta Therapeutics, Inc.Active, not recruiting
-
ML Bio Solutions, Inc.Virginia Commonwealth UniversityCompletedMuscular Dystrophies | Limb Girdle Muscular DystrophyUnited States, Denmark
-
Neurogen Brain and Spine InstituteWithdrawn
-
Rigshospitalet, DenmarkRecruitingLimb Girdle Muscular DystrophyDenmark
-
Sarepta Therapeutics, Inc.RecruitingLimb-girdle Muscular DystrophyUnited States
-
Rigshospitalet, DenmarkCompleted
Clinical Trials on cytokines dosage
-
University Hospital, Strasbourg, FranceCompleted
-
Francis CorazzaCompleted
-
Assistance Publique - Hôpitaux de ParisRecruitingJuvenile DermatomyositisFrance
-
Assiut UniversityUnknownRetinopathy of Prematurity
-
Centre Hospitalier Universitaire de Saint EtienneTerminatedNasal Polyps | Chronic Rhinosinusitis With Nasal Polyps | Olfaction DisordersFrance
-
University Hospital, AngersPoitiers University Hospital; University Hospital, Brest; Rennes University Hospital and other collaboratorsNot yet recruiting
-
Charles University, Czech RepublicRecruitingSepsis | Immune Deficiency | Immunologic Paralysis | Immunologic SuppressionCzechia
-
University Hospital, Basel, SwitzerlandSchulzahnklinik Basel; Volkszahnklinik BaselCompleted
-
NYU Langone HealthCompletedMetastatic Malignant Melanoma
-
IRCCS Policlinico S. DonatoRecruiting